These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17937629)

  • 1. Current trends in immunosuppression.
    González Posada JM
    Nefrologia; 2006; 26 Suppl 2():3-8. PubMed ID: 17937629
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus, the first mTOR inhibitor.
    Sánchez-Plumed JA; González Molina M; Alonso A; Arias M
    Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunosuppression in kidney transplantation].
    Legendre C; Zuber J; Anglicheau D; Le Quintrec M; Martinez F; Mamzer-Bruneel MF; Thervet E
    Ann Urol (Paris); 2007 Dec; 41(6):276-84. PubMed ID: 18457319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
    Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 6. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA; Ross HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus use in de "novo renal" transplantation.
    Grinyo JM; Alonso A; Arias M; Campistol JM; González Molina M; González Posada JM; Morales JM; Oppenheimer F; Sánchez Fructuoso A; Sánchez-Plumed J; Ruiz JC
    Nefrologia; 2006; 26 Suppl 2():33-51. PubMed ID: 17937633
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunosuppression for kidney transplant recipients: current strategies].
    Alberú J; Urrea EM
    Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunosuppressors].
    Sánchez-Fructuoso AI
    Nefrologia; 2008; 28 Suppl 5():21-5. PubMed ID: 18847416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
    Vincenti F
    Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
    [No Abstract]   [Full Text] [Related]  

  • 11. [Everolimus: immunosuppression with antilymphoproliferative therapy].
    Pascual J
    Nefrologia; 2004; 24(2):112-23. PubMed ID: 15219086
    [No Abstract]   [Full Text] [Related]  

  • 12. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Everolimus and azoospermia, a causal relationship? About one case in a renal transplant patient].
    Wetzstein M; Weestel PF; Choukroun G
    Nephrol Ther; 2014 Feb; 10(1):44-5. PubMed ID: 24374233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 15. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 17. [Toward individualized immunosuppression].
    Grinyó JM
    Nefrologia; 2001; 21(3):232. PubMed ID: 11471302
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion to sirolimus.
    Ruiz JC; Alonso A; Arias M; Campistol JM; González Molina M; González Posada JM; Grinyo JM; Morales JM; Oppenheimer F; Sánchez Fructuoso A; Sánchez-Plumed J
    Nefrologia; 2006; 26 Suppl 2():52-63. PubMed ID: 17937634
    [No Abstract]   [Full Text] [Related]  

  • 19. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evidences in immunosuppression in the maintenance of renal transplantation].
    Hernández D; González-Posada JM
    Nefrologia; 2005; 25(4):369-80. PubMed ID: 16231502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.